The right biologic, first time.

Munus predicts which of 14+ competing biologics will work for which IBD patient — before the patient takes it. Precision biologic intelligence for autoimmune medicine.

Talk to us How it works

The problem

Half of IBD patients fail their first biologic.

Each failed prescription costs the payer $30–50K and the patient 6–12 months of preventable disease progression. Pharma loses brand share to competitors with every non-responder switch. No diagnostic exists to predict which biologic will work for which patient — and clinicians prescribe by guideline, not patient biology.

$30–40B

Global IBD biologic spend / yr

Plus $150–200B adjacent autoimmune.

50–65%

First-line failure rate

Patients cycle 2–3 drugs before remission.

$8–12B

US payer waste / yr

Half on failed drugs, half on the surgeries that follow.

+5–7%

YoY disease growth

Pediatric IBD up 8–10%/yr globally.

The solution

An inference engine that matches each patient to their biologic.

Munus integrates pathway phenotype (Th1, Th17, NF-κB, NLRP3, etc.), prior drug-response history, exposure signature, and symptom pattern into a structured inference model that ranks 14+ competing biologics by predicted clinical response. Built for the clinician at the point of care.

Step 1

Upload chart

Drop patient files (PDF, DOCX, DICOM). Munus de-identifies automatically and extracts structured findings from unstructured records.

Step 2

Review match

Algorithm produces a ranked biologic recommendation with predicted response %. Top match plus alternatives, each with clinical rationale.

Step 3

Prescribe

Export the prior-auth-ready clinical brief with rationale, dosing, and payer documentation. Direct to EMR or share with the patient.

Market validation

The playbook is proven in oncology.

Three precision-medicine platforms in oncology have validated the model. Same three-channel non-exclusive structure Munus runs in autoimmune.

Tempus AI · NASDAQ: TEM

$700M

ARR · $8–12B market cap · 30%+ YoY growth · 5 non-exclusive big-pharma partners.

Foundation Medicine

$2.4B

Acquired by Roche in 2018. Companion diagnostic + non-exclusive pharma data partnerships.

Flatiron Health

$1.9B

Acquired by Roche in 2018. Real-world oncology data and analytics platform.

Why Munus wins

An empty quadrant, a defensible algorithm, a built moat.

First-mover in autoimmune

Tempus and Foundation own oncology. Recursion and Insitro own drug discovery. No incumbent owns autoimmune + point-of-care. That's the Munus quadrant — and it's a $30–40B market.

Multi-modal inference engine

Most precision medicine is genomic only. Munus integrates pathway phenotype, prior drug-response history, exposure signature, and symptom pattern into a single inference layer that no genomic-only competitor can match.

Three customers · one algorithm

Same algorithm packaged for clinicians ($1,200/test), pharma ($5–50M per partnership, non-exclusive), and payers ($0.1–10M annual contracts). The Tempus playbook applied to autoimmune.

Live customer cohort

The Gut Health Solution clinic is Munus's first customer. Real cases generate the real-world outcomes data flywheel that pharma and payers will pay to access in Phase 2 and Phase 3.